Impact of short-course therapy on tuberculosis drug resistance in South-West Burkina Faso
Setting: The Regional Tuberculosis Centre and the Muraz Centre in Bobo-Dioulasso, Burkina Faso. Objectives: To observe the trend of primary drug resistance in pulmonary tuberculosis patients 5 years into a short-course treatment programme and to assess the possible implementation of a further progra...
Gespeichert in:
| Veröffentlicht in: | Tubercle and lung disease 1996-10, Vol.77 (5), p.429-436 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 436 |
|---|---|
| container_issue | 5 |
| container_start_page | 429 |
| container_title | Tubercle and lung disease |
| container_volume | 77 |
| creator | Ledru, S. Cauchoix, B. Yaméogo, M. Zoubga, A. Lamandé-Chiron, J. Portaels, F. Chiron, J.P. |
| description | Setting: The Regional Tuberculosis Centre and the Muraz Centre in Bobo-Dioulasso, Burkina Faso.
Objectives: To observe the trend of primary drug resistance in pulmonary tuberculosis patients 5 years into a short-course treatment programme and to assess the possible implementation of a further programme.
Design: Bacteriological study of stains isolated from all newly diagnosed tuberculosis patients (
n = 300), all relapse cases (
n = 20) and all failure cases (
n = 58) from the Houet province, during the period from April 1992 to April 1994. Human immunodeficiency virus (HIV) serostatus was determined for the first 119 patients included in the study.
Results:Mycobacterium tuberculosis was the predominant species as shown by 75.1% of the isolates; next was
M. africanum, then atypical mycobacteria and finally
M. bovis, representing 18.4%, 6.5% and 0.4% of the isolates respectively. Primary resistance (excluding atypical strains) was as follows: isoniazid 7.6%, ethambutol 1.0%, rifampicin 2.5%, and streptomycin 12.4%; 33.6% of the patients tested for HIV were HIV positive. There was no relationship between HIV serostatus and the identity of strains or drug resistance. However, negative acid-fast bacilli smear microscopy with positive culture was significantly more frequent in HIV-positive patients than in HIV-negative patients.
Conclusion: This study shows a drop in primary resistance compared with previous studies carried out in Bobo-Dioulasso under the same conditions (setting, materials and methods, sampling procedures) in 1982 and 1986. This is consistent with the hypothesis that treatment monitoring and the introduction of short-course therapy in 1989 (2 HERZ/4 HR or 2 HRSZ/4 HR) have contributed to lower rates of primary drug resistance.
Cadre: Le Centre Régional de Lutte Antituberculeuse et le Centre Muraz, à Bobo-Dioulasso, en Burkina Faso.
Objet: Etudier l'évolution des résistances primaires chez les patients tuberculeux pulmonaires 5 ans après la mise en route d'un schéma thérapeutique de courte durée ainsi que l'opportunité de la mise en place d'un nouveau schéma.
Schéma: Etude bactériologique des souches isolées de tous les patients tuberculeux, originaires de la province du Houet, entre avril 1992 et avril 1994, qu'il s'agisse du premier traitement (
n = 300), d'une rechute (
n = 20) ou d'un échec thérapeutique (
n = 58). Les 119 premiers patients inclus ont bénéficié d'une sérologie HIV.
Résultats: Mycobacterium tuberculosis est l'espèce la plus |
| doi_str_mv | 10.1016/S0962-8479(96)90116-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78612028</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0962847996901161</els_id><sourcerecordid>15786285</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-7accf7e43b0cb67e4d8384121a03f20c171cdabf1d2082f93ea8bee3d99efab73</originalsourceid><addsrcrecordid>eNqFkEtrGzEURkVoSB2nP8GgVWgW0-pqXtIqpCEvCHThhrYrodHcidXYI1ePQP595Nh469X94J774BAyA_YNGDTf50w2vBBVK7_K5kIygKaAIzKBuuQFB_nnE5nskc_kNIR_jDFeNdUJORGyllC1E_L3YbXWJlI30LBwPhbGJR-QxgV6vX6jbqQxdehNWrpgA-19eqYec4x6NEjtSOcuxUXxG0OkP5J_saOmtzq4M3I86GXAL7s6JU-3N7-u74vHn3cP11ePhSklxKLVxgwtVmXHTNfk0ItSVMBBs3LgzEALptfdAD1ngg-yRC06xLKXEgfdteWUnG_3rr37n_IXamWDweVSj-hSUK1ogDMuDoJQZ5SLOoP1FjTeheBxUGtvV9q_KWBq4159uFcbsUo26sO9gjw32x1I3Qr7_dROdu5fbvuYdbxa9CoYi9libz2aqHpnD1x4B3-ylWI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15786285</pqid></control><display><type>article</type><title>Impact of short-course therapy on tuberculosis drug resistance in South-West Burkina Faso</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Ledru, S. ; Cauchoix, B. ; Yaméogo, M. ; Zoubga, A. ; Lamandé-Chiron, J. ; Portaels, F. ; Chiron, J.P.</creator><creatorcontrib>Ledru, S. ; Cauchoix, B. ; Yaméogo, M. ; Zoubga, A. ; Lamandé-Chiron, J. ; Portaels, F. ; Chiron, J.P.</creatorcontrib><description>Setting: The Regional Tuberculosis Centre and the Muraz Centre in Bobo-Dioulasso, Burkina Faso.
Objectives: To observe the trend of primary drug resistance in pulmonary tuberculosis patients 5 years into a short-course treatment programme and to assess the possible implementation of a further programme.
Design: Bacteriological study of stains isolated from all newly diagnosed tuberculosis patients (
n = 300), all relapse cases (
n = 20) and all failure cases (
n = 58) from the Houet province, during the period from April 1992 to April 1994. Human immunodeficiency virus (HIV) serostatus was determined for the first 119 patients included in the study.
Results:Mycobacterium tuberculosis was the predominant species as shown by 75.1% of the isolates; next was
M. africanum, then atypical mycobacteria and finally
M. bovis, representing 18.4%, 6.5% and 0.4% of the isolates respectively. Primary resistance (excluding atypical strains) was as follows: isoniazid 7.6%, ethambutol 1.0%, rifampicin 2.5%, and streptomycin 12.4%; 33.6% of the patients tested for HIV were HIV positive. There was no relationship between HIV serostatus and the identity of strains or drug resistance. However, negative acid-fast bacilli smear microscopy with positive culture was significantly more frequent in HIV-positive patients than in HIV-negative patients.
Conclusion: This study shows a drop in primary resistance compared with previous studies carried out in Bobo-Dioulasso under the same conditions (setting, materials and methods, sampling procedures) in 1982 and 1986. This is consistent with the hypothesis that treatment monitoring and the introduction of short-course therapy in 1989 (2 HERZ/4 HR or 2 HRSZ/4 HR) have contributed to lower rates of primary drug resistance.
Cadre: Le Centre Régional de Lutte Antituberculeuse et le Centre Muraz, à Bobo-Dioulasso, en Burkina Faso.
Objet: Etudier l'évolution des résistances primaires chez les patients tuberculeux pulmonaires 5 ans après la mise en route d'un schéma thérapeutique de courte durée ainsi que l'opportunité de la mise en place d'un nouveau schéma.
Schéma: Etude bactériologique des souches isolées de tous les patients tuberculeux, originaires de la province du Houet, entre avril 1992 et avril 1994, qu'il s'agisse du premier traitement (
n = 300), d'une rechute (
n = 20) ou d'un échec thérapeutique (
n = 58). Les 119 premiers patients inclus ont bénéficié d'une sérologie HIV.
Résultats: Mycobacterium tuberculosis est l'espèce la plus fréquemment rencontrée: 75,1% des isolements; viennent ensuite
M. africanum, les mycobactéries atypiques et enfin
M. bovis avec respectivement 18,4%, 6,5% et 0,4% des isolements. Les résistances primaires pour les souches du complexe
M. tuberculosis sont les suivantes: isoniazide 7,6%, ethambutol 1%, rifampicine 2,5% et streptomycine 12,4%. 33,6% des 119 patients testés pour le VIH étaient positifs. Il n'y avait pas de relation entre le statut sérologique et l'espèce isolée ou sa résistance aux antibiotiques. Par contre, le nombre de cultures positives avec examen direct négatif était significativement plus élevé chez les patients positifs pour le VIH.
Conclusion: Cette étude semble montrer que l'introduction d'un régime de courte durée à Bobo-Dioulasso en 1989 (2 HERZ/4 HR ou 2HRSZ/4 HR), ainsi que la stricte supervision du traitement en première phase, ont contribuéà la diminution des résistances primaires constatée par rapport à d'autres études réalisées à BoboDioulasso en 1982 et 1986 dans les mêmes conditions (cadre, matériel et méthodes, échantillonnage).
Marco de referencia: Centro Regional de Control de la Tuberculosis en Bobo-Dioulasso y el Centro Muraz.
Objetivo: Observar la tendencia de la resistencia primaria en pacientes con tuberculosis pulmonar 5 años después de la implantación de un programa de tratamiento con un esquema de corta duración y evaluar la oportunidad de aplicar un nuevo programa.
Método: Estudio bacteriológico de cepas aisladas a partir de pacientes con tuberculosis recientemente diagnosticada (
n = 300), todos los casos de recaída (
n = 20) y todos los casos de fracaso del tratamiento (
n = 58), entre abril de 1992 y abril de 1994. Se determinó la serología VIH en los primeros 119 pacientes incluidos en el estudio.
Resultados: La especie predominante fue
Mycobacterium tuberculosis, encontrada en el 75,1% de los aislados, enseguida
M. africanum (18,4%), micobacterias atípicas (6,5%), y finalmente
M. bovis (0,4%). La resistencia primaria para las cepas del complejo
M. tuberculosis fue la siguiente : isoniacida 7,6%, etambutol 1,0%, rifampicina 2,5%, y estreptomicina 12,4%. El 33,6% de los 119 pacientes sometidos al test VIH eran positivos. No se encontró una relación entre la situación con respecto al VIH y la identidad de la cepa aislada o su resistencia a los medicamentos. Sin embargo, el número de casos con baciloscopia negativa y cultivo positivo era significativamente más elevado en los pacientes VIH-positivos.
Conclusion: Este estudio parece mostrar que en Bobo-Dioulasso, la introducción en 1989 de un régimen de corta duración (2HERZ/4HR or 2HRSZ/4HR), así como la supervision estricta del tratamiento en la fase intensiva, han contribuido a una reducción de la resistencia primaria, comparada con estudios previos realizados en Bobo-Dioulasso en 1982 y 1986, en las mismas condiciones (contexto, material y método, procedimiento de muestreo).</description><identifier>ISSN: 0962-8479</identifier><identifier>EISSN: 1532-219X</identifier><identifier>DOI: 10.1016/S0962-8479(96)90116-1</identifier><identifier>PMID: 8959147</identifier><language>eng</language><publisher>Scotland: Elsevier Ltd</publisher><subject>Adult ; AIDS-Related Opportunistic Infections - drug therapy ; AIDS-Related Opportunistic Infections - microbiology ; AIDS/HIV ; Antitubercular Agents - pharmacology ; Antitubercular Agents - therapeutic use ; Burkina Faso - epidemiology ; Drug Administration Schedule ; Drug Resistance, Microbial ; Female ; Humans ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Mycobacterium - classification ; Mycobacterium africanum ; Mycobacterium tuberculosis ; Mycobacterium tuberculosis - drug effects ; Mycobacterium tuberculosis - isolation & purification ; Sputum - microbiology ; Tuberculosis, Multidrug-Resistant - epidemiology ; Tuberculosis, Pulmonary - drug therapy ; Tuberculosis, Pulmonary - microbiology</subject><ispartof>Tubercle and lung disease, 1996-10, Vol.77 (5), p.429-436</ispartof><rights>1996</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-7accf7e43b0cb67e4d8384121a03f20c171cdabf1d2082f93ea8bee3d99efab73</citedby><cites>FETCH-LOGICAL-c391t-7accf7e43b0cb67e4d8384121a03f20c171cdabf1d2082f93ea8bee3d99efab73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8959147$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ledru, S.</creatorcontrib><creatorcontrib>Cauchoix, B.</creatorcontrib><creatorcontrib>Yaméogo, M.</creatorcontrib><creatorcontrib>Zoubga, A.</creatorcontrib><creatorcontrib>Lamandé-Chiron, J.</creatorcontrib><creatorcontrib>Portaels, F.</creatorcontrib><creatorcontrib>Chiron, J.P.</creatorcontrib><title>Impact of short-course therapy on tuberculosis drug resistance in South-West Burkina Faso</title><title>Tubercle and lung disease</title><addtitle>Tuber Lung Dis</addtitle><description>Setting: The Regional Tuberculosis Centre and the Muraz Centre in Bobo-Dioulasso, Burkina Faso.
Objectives: To observe the trend of primary drug resistance in pulmonary tuberculosis patients 5 years into a short-course treatment programme and to assess the possible implementation of a further programme.
Design: Bacteriological study of stains isolated from all newly diagnosed tuberculosis patients (
n = 300), all relapse cases (
n = 20) and all failure cases (
n = 58) from the Houet province, during the period from April 1992 to April 1994. Human immunodeficiency virus (HIV) serostatus was determined for the first 119 patients included in the study.
Results:Mycobacterium tuberculosis was the predominant species as shown by 75.1% of the isolates; next was
M. africanum, then atypical mycobacteria and finally
M. bovis, representing 18.4%, 6.5% and 0.4% of the isolates respectively. Primary resistance (excluding atypical strains) was as follows: isoniazid 7.6%, ethambutol 1.0%, rifampicin 2.5%, and streptomycin 12.4%; 33.6% of the patients tested for HIV were HIV positive. There was no relationship between HIV serostatus and the identity of strains or drug resistance. However, negative acid-fast bacilli smear microscopy with positive culture was significantly more frequent in HIV-positive patients than in HIV-negative patients.
Conclusion: This study shows a drop in primary resistance compared with previous studies carried out in Bobo-Dioulasso under the same conditions (setting, materials and methods, sampling procedures) in 1982 and 1986. This is consistent with the hypothesis that treatment monitoring and the introduction of short-course therapy in 1989 (2 HERZ/4 HR or 2 HRSZ/4 HR) have contributed to lower rates of primary drug resistance.
Cadre: Le Centre Régional de Lutte Antituberculeuse et le Centre Muraz, à Bobo-Dioulasso, en Burkina Faso.
Objet: Etudier l'évolution des résistances primaires chez les patients tuberculeux pulmonaires 5 ans après la mise en route d'un schéma thérapeutique de courte durée ainsi que l'opportunité de la mise en place d'un nouveau schéma.
Schéma: Etude bactériologique des souches isolées de tous les patients tuberculeux, originaires de la province du Houet, entre avril 1992 et avril 1994, qu'il s'agisse du premier traitement (
n = 300), d'une rechute (
n = 20) ou d'un échec thérapeutique (
n = 58). Les 119 premiers patients inclus ont bénéficié d'une sérologie HIV.
Résultats: Mycobacterium tuberculosis est l'espèce la plus fréquemment rencontrée: 75,1% des isolements; viennent ensuite
M. africanum, les mycobactéries atypiques et enfin
M. bovis avec respectivement 18,4%, 6,5% et 0,4% des isolements. Les résistances primaires pour les souches du complexe
M. tuberculosis sont les suivantes: isoniazide 7,6%, ethambutol 1%, rifampicine 2,5% et streptomycine 12,4%. 33,6% des 119 patients testés pour le VIH étaient positifs. Il n'y avait pas de relation entre le statut sérologique et l'espèce isolée ou sa résistance aux antibiotiques. Par contre, le nombre de cultures positives avec examen direct négatif était significativement plus élevé chez les patients positifs pour le VIH.
Conclusion: Cette étude semble montrer que l'introduction d'un régime de courte durée à Bobo-Dioulasso en 1989 (2 HERZ/4 HR ou 2HRSZ/4 HR), ainsi que la stricte supervision du traitement en première phase, ont contribuéà la diminution des résistances primaires constatée par rapport à d'autres études réalisées à BoboDioulasso en 1982 et 1986 dans les mêmes conditions (cadre, matériel et méthodes, échantillonnage).
Marco de referencia: Centro Regional de Control de la Tuberculosis en Bobo-Dioulasso y el Centro Muraz.
Objetivo: Observar la tendencia de la resistencia primaria en pacientes con tuberculosis pulmonar 5 años después de la implantación de un programa de tratamiento con un esquema de corta duración y evaluar la oportunidad de aplicar un nuevo programa.
Método: Estudio bacteriológico de cepas aisladas a partir de pacientes con tuberculosis recientemente diagnosticada (
n = 300), todos los casos de recaída (
n = 20) y todos los casos de fracaso del tratamiento (
n = 58), entre abril de 1992 y abril de 1994. Se determinó la serología VIH en los primeros 119 pacientes incluidos en el estudio.
Resultados: La especie predominante fue
Mycobacterium tuberculosis, encontrada en el 75,1% de los aislados, enseguida
M. africanum (18,4%), micobacterias atípicas (6,5%), y finalmente
M. bovis (0,4%). La resistencia primaria para las cepas del complejo
M. tuberculosis fue la siguiente : isoniacida 7,6%, etambutol 1,0%, rifampicina 2,5%, y estreptomicina 12,4%. El 33,6% de los 119 pacientes sometidos al test VIH eran positivos. No se encontró una relación entre la situación con respecto al VIH y la identidad de la cepa aislada o su resistencia a los medicamentos. Sin embargo, el número de casos con baciloscopia negativa y cultivo positivo era significativamente más elevado en los pacientes VIH-positivos.
Conclusion: Este estudio parece mostrar que en Bobo-Dioulasso, la introducción en 1989 de un régimen de corta duración (2HERZ/4HR or 2HRSZ/4HR), así como la supervision estricta del tratamiento en la fase intensiva, han contribuido a una reducción de la resistencia primaria, comparada con estudios previos realizados en Bobo-Dioulasso en 1982 y 1986, en las mismas condiciones (contexto, material y método, procedimiento de muestreo).</description><subject>Adult</subject><subject>AIDS-Related Opportunistic Infections - drug therapy</subject><subject>AIDS-Related Opportunistic Infections - microbiology</subject><subject>AIDS/HIV</subject><subject>Antitubercular Agents - pharmacology</subject><subject>Antitubercular Agents - therapeutic use</subject><subject>Burkina Faso - epidemiology</subject><subject>Drug Administration Schedule</subject><subject>Drug Resistance, Microbial</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Microbial Sensitivity Tests</subject><subject>Middle Aged</subject><subject>Mycobacterium - classification</subject><subject>Mycobacterium africanum</subject><subject>Mycobacterium tuberculosis</subject><subject>Mycobacterium tuberculosis - drug effects</subject><subject>Mycobacterium tuberculosis - isolation & purification</subject><subject>Sputum - microbiology</subject><subject>Tuberculosis, Multidrug-Resistant - epidemiology</subject><subject>Tuberculosis, Pulmonary - drug therapy</subject><subject>Tuberculosis, Pulmonary - microbiology</subject><issn>0962-8479</issn><issn>1532-219X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtrGzEURkVoSB2nP8GgVWgW0-pqXtIqpCEvCHThhrYrodHcidXYI1ePQP595Nh469X94J774BAyA_YNGDTf50w2vBBVK7_K5kIygKaAIzKBuuQFB_nnE5nskc_kNIR_jDFeNdUJORGyllC1E_L3YbXWJlI30LBwPhbGJR-QxgV6vX6jbqQxdehNWrpgA-19eqYec4x6NEjtSOcuxUXxG0OkP5J_saOmtzq4M3I86GXAL7s6JU-3N7-u74vHn3cP11ePhSklxKLVxgwtVmXHTNfk0ItSVMBBs3LgzEALptfdAD1ngg-yRC06xLKXEgfdteWUnG_3rr37n_IXamWDweVSj-hSUK1ogDMuDoJQZ5SLOoP1FjTeheBxUGtvV9q_KWBq4159uFcbsUo26sO9gjw32x1I3Qr7_dROdu5fbvuYdbxa9CoYi9libz2aqHpnD1x4B3-ylWI</recordid><startdate>19961001</startdate><enddate>19961001</enddate><creator>Ledru, S.</creator><creator>Cauchoix, B.</creator><creator>Yaméogo, M.</creator><creator>Zoubga, A.</creator><creator>Lamandé-Chiron, J.</creator><creator>Portaels, F.</creator><creator>Chiron, J.P.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope><scope>7X8</scope></search><sort><creationdate>19961001</creationdate><title>Impact of short-course therapy on tuberculosis drug resistance in South-West Burkina Faso</title><author>Ledru, S. ; Cauchoix, B. ; Yaméogo, M. ; Zoubga, A. ; Lamandé-Chiron, J. ; Portaels, F. ; Chiron, J.P.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-7accf7e43b0cb67e4d8384121a03f20c171cdabf1d2082f93ea8bee3d99efab73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>AIDS-Related Opportunistic Infections - drug therapy</topic><topic>AIDS-Related Opportunistic Infections - microbiology</topic><topic>AIDS/HIV</topic><topic>Antitubercular Agents - pharmacology</topic><topic>Antitubercular Agents - therapeutic use</topic><topic>Burkina Faso - epidemiology</topic><topic>Drug Administration Schedule</topic><topic>Drug Resistance, Microbial</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Microbial Sensitivity Tests</topic><topic>Middle Aged</topic><topic>Mycobacterium - classification</topic><topic>Mycobacterium africanum</topic><topic>Mycobacterium tuberculosis</topic><topic>Mycobacterium tuberculosis - drug effects</topic><topic>Mycobacterium tuberculosis - isolation & purification</topic><topic>Sputum - microbiology</topic><topic>Tuberculosis, Multidrug-Resistant - epidemiology</topic><topic>Tuberculosis, Pulmonary - drug therapy</topic><topic>Tuberculosis, Pulmonary - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ledru, S.</creatorcontrib><creatorcontrib>Cauchoix, B.</creatorcontrib><creatorcontrib>Yaméogo, M.</creatorcontrib><creatorcontrib>Zoubga, A.</creatorcontrib><creatorcontrib>Lamandé-Chiron, J.</creatorcontrib><creatorcontrib>Portaels, F.</creatorcontrib><creatorcontrib>Chiron, J.P.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><collection>MEDLINE - Academic</collection><jtitle>Tubercle and lung disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ledru, S.</au><au>Cauchoix, B.</au><au>Yaméogo, M.</au><au>Zoubga, A.</au><au>Lamandé-Chiron, J.</au><au>Portaels, F.</au><au>Chiron, J.P.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Impact of short-course therapy on tuberculosis drug resistance in South-West Burkina Faso</atitle><jtitle>Tubercle and lung disease</jtitle><addtitle>Tuber Lung Dis</addtitle><date>1996-10-01</date><risdate>1996</risdate><volume>77</volume><issue>5</issue><spage>429</spage><epage>436</epage><pages>429-436</pages><issn>0962-8479</issn><eissn>1532-219X</eissn><abstract>Setting: The Regional Tuberculosis Centre and the Muraz Centre in Bobo-Dioulasso, Burkina Faso.
Objectives: To observe the trend of primary drug resistance in pulmonary tuberculosis patients 5 years into a short-course treatment programme and to assess the possible implementation of a further programme.
Design: Bacteriological study of stains isolated from all newly diagnosed tuberculosis patients (
n = 300), all relapse cases (
n = 20) and all failure cases (
n = 58) from the Houet province, during the period from April 1992 to April 1994. Human immunodeficiency virus (HIV) serostatus was determined for the first 119 patients included in the study.
Results:Mycobacterium tuberculosis was the predominant species as shown by 75.1% of the isolates; next was
M. africanum, then atypical mycobacteria and finally
M. bovis, representing 18.4%, 6.5% and 0.4% of the isolates respectively. Primary resistance (excluding atypical strains) was as follows: isoniazid 7.6%, ethambutol 1.0%, rifampicin 2.5%, and streptomycin 12.4%; 33.6% of the patients tested for HIV were HIV positive. There was no relationship between HIV serostatus and the identity of strains or drug resistance. However, negative acid-fast bacilli smear microscopy with positive culture was significantly more frequent in HIV-positive patients than in HIV-negative patients.
Conclusion: This study shows a drop in primary resistance compared with previous studies carried out in Bobo-Dioulasso under the same conditions (setting, materials and methods, sampling procedures) in 1982 and 1986. This is consistent with the hypothesis that treatment monitoring and the introduction of short-course therapy in 1989 (2 HERZ/4 HR or 2 HRSZ/4 HR) have contributed to lower rates of primary drug resistance.
Cadre: Le Centre Régional de Lutte Antituberculeuse et le Centre Muraz, à Bobo-Dioulasso, en Burkina Faso.
Objet: Etudier l'évolution des résistances primaires chez les patients tuberculeux pulmonaires 5 ans après la mise en route d'un schéma thérapeutique de courte durée ainsi que l'opportunité de la mise en place d'un nouveau schéma.
Schéma: Etude bactériologique des souches isolées de tous les patients tuberculeux, originaires de la province du Houet, entre avril 1992 et avril 1994, qu'il s'agisse du premier traitement (
n = 300), d'une rechute (
n = 20) ou d'un échec thérapeutique (
n = 58). Les 119 premiers patients inclus ont bénéficié d'une sérologie HIV.
Résultats: Mycobacterium tuberculosis est l'espèce la plus fréquemment rencontrée: 75,1% des isolements; viennent ensuite
M. africanum, les mycobactéries atypiques et enfin
M. bovis avec respectivement 18,4%, 6,5% et 0,4% des isolements. Les résistances primaires pour les souches du complexe
M. tuberculosis sont les suivantes: isoniazide 7,6%, ethambutol 1%, rifampicine 2,5% et streptomycine 12,4%. 33,6% des 119 patients testés pour le VIH étaient positifs. Il n'y avait pas de relation entre le statut sérologique et l'espèce isolée ou sa résistance aux antibiotiques. Par contre, le nombre de cultures positives avec examen direct négatif était significativement plus élevé chez les patients positifs pour le VIH.
Conclusion: Cette étude semble montrer que l'introduction d'un régime de courte durée à Bobo-Dioulasso en 1989 (2 HERZ/4 HR ou 2HRSZ/4 HR), ainsi que la stricte supervision du traitement en première phase, ont contribuéà la diminution des résistances primaires constatée par rapport à d'autres études réalisées à BoboDioulasso en 1982 et 1986 dans les mêmes conditions (cadre, matériel et méthodes, échantillonnage).
Marco de referencia: Centro Regional de Control de la Tuberculosis en Bobo-Dioulasso y el Centro Muraz.
Objetivo: Observar la tendencia de la resistencia primaria en pacientes con tuberculosis pulmonar 5 años después de la implantación de un programa de tratamiento con un esquema de corta duración y evaluar la oportunidad de aplicar un nuevo programa.
Método: Estudio bacteriológico de cepas aisladas a partir de pacientes con tuberculosis recientemente diagnosticada (
n = 300), todos los casos de recaída (
n = 20) y todos los casos de fracaso del tratamiento (
n = 58), entre abril de 1992 y abril de 1994. Se determinó la serología VIH en los primeros 119 pacientes incluidos en el estudio.
Resultados: La especie predominante fue
Mycobacterium tuberculosis, encontrada en el 75,1% de los aislados, enseguida
M. africanum (18,4%), micobacterias atípicas (6,5%), y finalmente
M. bovis (0,4%). La resistencia primaria para las cepas del complejo
M. tuberculosis fue la siguiente : isoniacida 7,6%, etambutol 1,0%, rifampicina 2,5%, y estreptomicina 12,4%. El 33,6% de los 119 pacientes sometidos al test VIH eran positivos. No se encontró una relación entre la situación con respecto al VIH y la identidad de la cepa aislada o su resistencia a los medicamentos. Sin embargo, el número de casos con baciloscopia negativa y cultivo positivo era significativamente más elevado en los pacientes VIH-positivos.
Conclusion: Este estudio parece mostrar que en Bobo-Dioulasso, la introducción en 1989 de un régimen de corta duración (2HERZ/4HR or 2HRSZ/4HR), así como la supervision estricta del tratamiento en la fase intensiva, han contribuido a una reducción de la resistencia primaria, comparada con estudios previos realizados en Bobo-Dioulasso en 1982 y 1986, en las mismas condiciones (contexto, material y método, procedimiento de muestreo).</abstract><cop>Scotland</cop><pub>Elsevier Ltd</pub><pmid>8959147</pmid><doi>10.1016/S0962-8479(96)90116-1</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0962-8479 |
| ispartof | Tubercle and lung disease, 1996-10, Vol.77 (5), p.429-436 |
| issn | 0962-8479 1532-219X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_78612028 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult AIDS-Related Opportunistic Infections - drug therapy AIDS-Related Opportunistic Infections - microbiology AIDS/HIV Antitubercular Agents - pharmacology Antitubercular Agents - therapeutic use Burkina Faso - epidemiology Drug Administration Schedule Drug Resistance, Microbial Female Humans Male Microbial Sensitivity Tests Middle Aged Mycobacterium - classification Mycobacterium africanum Mycobacterium tuberculosis Mycobacterium tuberculosis - drug effects Mycobacterium tuberculosis - isolation & purification Sputum - microbiology Tuberculosis, Multidrug-Resistant - epidemiology Tuberculosis, Pulmonary - drug therapy Tuberculosis, Pulmonary - microbiology |
| title | Impact of short-course therapy on tuberculosis drug resistance in South-West Burkina Faso |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T07%3A58%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Impact%20of%20short-course%20therapy%20on%20tuberculosis%20drug%20resistance%20in%20South-West%20Burkina%20Faso&rft.jtitle=Tubercle%20and%20lung%20disease&rft.au=Ledru,%20S.&rft.date=1996-10-01&rft.volume=77&rft.issue=5&rft.spage=429&rft.epage=436&rft.pages=429-436&rft.issn=0962-8479&rft.eissn=1532-219X&rft_id=info:doi/10.1016/S0962-8479(96)90116-1&rft_dat=%3Cproquest_cross%3E15786285%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15786285&rft_id=info:pmid/8959147&rft_els_id=S0962847996901161&rfr_iscdi=true |